Apr 11, 2019
90 Views
0 0

Diabetic Nephropathy Market to Witness Surge in Demand Owing to Rising End-use Adoption

Written by

Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020.

North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.

North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0 million in 2020, growing at a CAGR of 5.7% from 2014 to 2020.

The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD 2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020.

Request Sample [email protected]https://www.persistencemarketresearch.com/samples/3594

Diabetes is a disease characterized by high blood sugar level which is caused by improper functioning of the pancreas, the organ secreting insulin in the body. Diabetic nephropathy is a disease of the kidney glomerulus and happens to be one of the most significant complications in terms of mortality and morbidity for patients with diabetes. The disease is mainly characterized by macroalbuminuria, where in a single day presence of albumin in the urine increases over 300 milligrams. In addition, diabetic nephropathy is also caused by proteinuria, imbalanced glomerular filtration rate, and hypertension. The imbalanced glomerular filtration rate of the kidney builds up waste products in the blood and increases the level of protein in the urine. Signs and symptoms of diabetic nephropathy are unknown in early stage of the disease. However, major signs and symptoms of diabetic nephropathy in its later stages are increased albumin secretion in urine, high blood pressure, ankle and leg swelling, high level of blood urea nitrogen (BUN) and serum creatinine, itching, morning weakness, nausea, vomiting, and anemia. Disease modifying therapies (DMT) that employ angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used in the treatment of diabetic nephropathy. ACE inhibitors, such as enalapril, captopril, ramipril, and lisinopril, lower the amount of protein in the urine. ARBs and ACE inhibitors together provide greater protection to the kidney than they individually can. Major ARBs are candesartan, losartan and irbesartan.

Growing prevalence of diabetes and obesity, increasing R&D investments in drug discovery and development, and rising awareness about diabetes and kidney-related disorders are some of the major drivers of the diabetic nephropathy market. On the other hand, stringent regulatory requirements and longer approval time for drugs as well as a lack of comprehensive therapeutic management for diabetic nephropathy are major concerns for the market. Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market is the recent market trends that have been observed in diabetic nephropathy market.

North America has the largest market for diabetic nephropathy, followed by Europe. Some of the fastest growing markets for diabetic nephropathy are China and Japan. This is due to increase in the diabetic population and rise in incidence rates of various kidney diseases in these countries.

Request Report [email protected]://www.persistencemarketresearch.com/methodology/3594

Article Categories:
Health Care

Comments to Diabetic Nephropathy Market to Witness Surge in Demand Owing to Rising End-use Adoption

  • Thus, you need to hire a company that has the very best organic SEO services too offer.
    Your Install – Aware installation will obtain the Web Media
    Blocks successfully in the event the target machine can “download” them from with the specified URLs.
    The internet has been doing wonders in mareketing nowadays using its users spread worldwide.

    visite site April 13, 2019 10:41 am Reply

Leave a Reply

Your email address will not be published. Required fields are marked *